tbuckley/cabot-search huggingface dataset:
Abstract 2559: Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer
Authors: Judith Raimbourg, Mathilde Cabart, Marie-Pierre Joalland, Didier Decaudin, Ludmilla Deplater, Didier Lanoe, Jean-Yves Douillard, Jaafar Bennouna, François Vallette, Lisenn Lalier
Journal: Cancer Research (2015)

Abstract Background : Lung cancer is the first cause of cancer death worldwide. EGFR tyrosine kinase inhibitors (EGFR-TKI) have improved the survival of patient harboring EGFR activating mutations. Besides, EGFR-TKIs have shown clinical activity for patients with wild type EGFR (wtEGFR) tumors as maintenance treatment and for a fraction of them as second line treatment. These observations impel us to objective and document the mechanisms implicated in order to optimize the use of EGFR-TKI in the treatment of wtEGFR lung cancer. Methods : In vitro experiments rely on lung cancer cell lines expressing either wtEGFR or mutated EGFR. Their sensitivity to erlotinib in control conditions or short after a sublethal cisplatin treatment was studied. In vitro results were validated on lung patients-derived xenografts (PDX) with four wtEGFR human adenocarcinomas. Results : Cisplatin pretreatment enhances erlotinib toxicity in wtEGFR cells (providing its robust expression) but not in EGFR-mutated cells. Cisplatin priming increases erlotinib toxicity either through apoptosis or autophagy depending on the cell line. This sensitization correlates with an increase in EGFR expression and phosphorylation and a raise in AKT and Erk phosphorylation. The sensitization is also observed during long-term cisplatin treatment in a cisplatin-resistant subpopulation, together with concomitant EGFR pathway activation. The in vivo experiments conducted in PDX confirm that cisplatin pretreatment potentiates erlotinib in three of the four wtEGFR lung tumors models. Of note, the sensitization to erlotinib occured independently from KRas status. Conclusion : The sensitivity of the wtEGFR lung cancer cells and lung cancer xenografts to erlotinib is enhanced by cisplatin pretreatment, whatever the type of induced cell death. Cisplatin induces activation of EGFR and his downstream kinases AKT and Erk. This sensitization is independent from the tumor K-Ras status. EGFR phosphorylation could be a potential marker of this sensitization and might be predicitive of the optimal efficiency of EGFR TKI. In vivo validation of this marker is still ongoing. This study was supported by Roche laboratory and by the foundation for medical research. Citation Format: Judith Raimbourg, Mathilde Cabart, Marie-Pierre Joalland, Didier Decaudin, Ludmilla Deplater, Didier Lanoe, Jean-Yves Douillard, Jaafar Bennouna, François Vallette, Lisenn Lalier. Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2559. doi:10.1158/1538-7445.AM2015-2559
TCT-56 Validation of PARIS Risk Scores in a Large Multi-Ethnic PCI Cohort: Results from a Large Single-Center Registry
Authors: Usman Baber, Roxana Mehran, Serdar Farhan, Melissa Aquino, Jason Kovacic, Joseph Sweeny, Pedro Moreno, Srushti Shah, Pooja Vijay, George Dangas, Nitin Barman, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2016)
LP24 : Safety, efficacy and impact on liver function of simeprevir (SMV) in combination with daclatasvir (DCV) or sofosbuvir (SOF) in patients with severe hepatitis C recurrence after liver transplantation (LT): results from compassionate use in europe
Authors: M.-C. Londoño, K. Hezner, C. Moreno, P. Carrai, U. Visco Comadini, R. Lionetti Lionetti, V. Calvaruso, A.M. Elsharkawy, M. Sterneck, O. Weiland, C. Torti, M. Biolato, X. Forns
Journal: Journal of Hepatology (2015)
Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes
Authors: Jenny Aurielle B Babon, Megan E DeNicola, David M Blodgett, Inne Crèvecoeur, Thomas S Buttrick, René Maehr, Rita Bottino, Ali Naji, John Kaddis, Wassim Elyaman, Eddie A James, Rachana Haliyur, Marcela Brissova, Lut Overbergh, Chantal Mathieu, Thomas Delong, Kathryn Haskins, Alberto Pugliese, Martha Campbell-Thompson, Clayton Mathews, Mark A Atkinson, Alvin C Powers, David M Harlan, Sally C Kent
Journal: Nature Medicine (2016)
Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.
Authors: Francesco Buccisano, Luca Maurillo, Valter Gattei, Giovanni Del Poeta, Maria Ilaria Del Principe, Fraboni Fraboni, Paola Panetta, Maria Irno Consalvo, Selenia Campagna, Laura Giannì, Licia Ottaviani, Massimiliano Postorino, Paolo De Fabritiis, William Arcese, Francesco Lo Coco, Sergio Amadori, Adriano Venditti
Journal: Blood (2006)
The locum cap is working but we still have a long way to go
Authors: Kathy Mclean
Journal: BMJ (2016)

Kathy Mclean warns that NHS trusts are still using too many expensive agency staff 

Before NHS Improvement introduced controls aimed at reducing expenditure on agency staff in the NHS, trusts’ spending on such staff had been spiralling out of control, growing 25% on average year on year.

A year after the caps were introduced, we have made a difference and are starting to reap the benefits. Trusts up and down the country have worked hard to save a total of just over £600m to date. It’s a solid start, and we expect agency costs to continue to fall.

However, despite all this hard work the sector is still spending £250m a month on agencies. We believe that this is …
What exactly shortens stent patency in hilar block from gallbladder carcinoma?
Authors: Phonthep Angsuwatcharakon, Pradermchai Kongkam, Rungsun Rerknimitr
Journal: Endoscopy (2016)

Our group has read with interest the recent paper by Miura et al. entitled “Risk factors for recurrent biliary obstruction following placement of self-expandable metallic stents in patients with malignant perihilar biliary stricture” [1]. We appreciate this work and publication very much, and would like to make some comments regarding the paper.
TCT-724 Permanent Pacemaker Implantation after Transcatheter Aortic Valve Replacement – National Experience
Authors: Abhijeet Dhoble, Viraj Bhise, Prakash Balan, Tuyen C. Nguyen, Pranav Loyalka, Biswajit Kar, Richard Smalling
Journal: Journal of the American College of Cardiology (2016)
MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab -Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC
Authors: Michael Thomas, Ray Page, Laurent Gressot, Davey Daniel, Daniel Morgensztern, Benjamin Levy, Maen Hussein, Mohammad Razaq, Victoria M. Villaflor, Santiago P. Aix, Kulumani Sivarajan, Walburga Engel-Riedel, Peter Staib, Amy Ko, Teng J. Ong, Nataliya Trunova, David R. Spigel
Journal: Journal of Thoracic Oncology (2016)
Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Michael S Mathisen, Hagop M Kantarjian, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Gautam Borthakur, Jorge E. Cortes, Alfonso Quintás-Cardama
Journal: Blood (2011)
Phase I study of CPT11 and cisplatin with concurrent radiotherapy and adjuvant CPT11/cisplatin in small-cell lung cancer, limited disease
Authors: G. Klautke, S. Fähndrich, C. Büscher, C. Virchow, R. Fietkau
Journal: Journal of Clinical Oncology (2005)

7310 Background: CPT11 together with Cisplatinum has promising results in the teatmenz of SCLC. Concurrent chemoradiotherapy also shows a benefit compaired with sequential chemoradiotherapy in SCLC, LD. So we combine both elements in a Phase I-Study. Methods: 5 men and 5 women (age 44–66, mean 63 years) with SCLC, LD were treated as follows: conventionally fractionated radiation in shrinking field technique to a total dose of 54 Gy. CPT 11 was given over 90 minutes on day 1,8,15 and 29,36,43 during radiation with following dose levels: 40, 50, 60 mg/m2. Cisplatin was given at a fixed dose of 20mg/m2, day 1–3 and 29–31. On day 51 the same chemotherapy was given for 4 courses; in case of CR, PCI was also given. Dose-limiting toxicity (DLT) is defined as leukopenia grade IV, thrombopenia grade III, IV or any non-hematological toxicity grade III, IV (CTC). Results: There was no DLT during chemoradiotherapy. Hematological toxicity included only 1 leukopenia grade III. 1 patient gets a pneumonitis grade 2 (CTC). There was no worsening of the pulmonary function after chemoradiotherapy, in 2 cases there were even an improvement. After chemoradiotherapy we see 4 CR and 6 PR, and no systemical progression. Conclusions: Concurrent chemoradiotherapy and adjuvant chemotherapy with CPT11 (60mg/m2; d 1,8,15) and Cisplatin (20mg/m2; d1–3) is possible and seems to be very effective. So we go on in a Phase II-Study No significant financial relationships to disclose.
Vast majority of both smokers and non-smokers favour at least a partial ban
Authors: G. Waldron
Journal: BMJ (1996)

Van der Sijs-Bos and colleagues claim that our evidence is insufficient to challenge the specifi- city of prenatal diagnosis of Turner's syndrome karyotypes made by amniocentesis, but at the same time they present data that point in the same direction as our data.We must re-emphasise the conclusion of our paper: the only study that will resolve this ques- tion is one looking at every fetus with a prenatal diagnosis of a Turner's syndrome karyotype, with special reference to the distribution of cells in cases of mosaic karyotypes, results from karyotyping of aborted fetuses, and karyotyping of infants with the syndrome who have not yet been examined postnatally.
TCT-718 Predictors of vascular complications in women undergoing contemporary transcatheter aortic valve replacement: A report from the WIN-TAVI registry
Authors: Alaide Chieffo, Anna Sonia Petronio, Julinda Mehilli, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Patrizia Presbitero, Piera Capranzano, Didier Tchetche, Alessandro Iadanza, Gennaro Sardella, Nicolas Van Mieghem, Emanuele Meliga, Nicolas Dumonteil, Chiara Fraccaro, Daniela Trabattoni, Ghada Mikhail, Samin Sharma, M.C. Ferrer, Christoph Naber, Peter Kievit, Michela Faggioni, Marie-Claude Morice, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-673 Etiolgies for readmission and complications following Transcatheter Aortic Valve Replacement (TAVR): A Nationwide Perspective
Authors: Ekta Aneja, Nilay Patel, Shilpkumar Arora, Sopan Lahewala, Sidakpal Panaich, Chirag Savani, Kriti Narwal, Smit Patel, Kosha Thakore, Aditi Amin, Nileshkumar Patel, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2016)
Abstract 1850: Evaluation of Pim-1 kinase inhibition in a preclinical model of mouse prostate cancer
Authors: Marco A. De Velasco, Takashi Oki, Yurie Kura, Naomi Ando, Emiko Fukushima, Barry R. Davies, Dennis Huszar, Yutaka Yamamoto, Yuji Hatanaka, Nobutaka Shimizu, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research (2015)

Abstract Pim-1 is a serine/threonine kinase that is in involved in the transcription of genes that regulate apoptosis and cell cycle progression. Pim-1 has been shown to be overexpressed in a variety of cancers and has been implicated in human prostate tumorigenesis. The aim of our study was to clarify the role of Pim-1 during the prostate tumorigenesis and determine its potential as a molecular target for therapy. To accomplish this goal, we carried out a series of experiments using a genetically engineered mouse model of prostate cancer driven by the conditional inactivation of PTEN. High levels of Pim-1 were observed during the early stages of the tumorigenesis process which decreased as tumors progressed. Expression of Pim-1 was localized in the nucleus and cytoplasm of prostatic intraepithelial neoplasia (PIN), well-differentiated, and moderately-differentiated tumors. In poorly-differentiated tumors, Pim-1expression was heterogeneously expressed at lower levels and was predominantly localized to the cytoplasm of cancer cells. Levels of Pim-1 expression were increased in tumors from mice after surgical castration. To evaluate the therapeutic potential of Pim-1as a target for prostate cancer, we tested the antitumor effects of AZD1208, a highly potent Pim kinase inhibitor, on a panel of cell lines derived from castration-naïve and castration-resistant mouse prostate cancer. AZD1208 inhibited the tumor cell growth of several cell lines and demonstrated higher sensitivity to those derived from castration resistant tumors. In vivo, drug intervention studies show that treatment with AZD1208 reduced tumor growth of castration-naïve and castration-resistant prostate tumors by 12.1 (P = 0.162) and 24.3% (P&amp;lt;0.001), respectively. These findings provide further support for a role of Pim-1 during prostate tumorigenesis and could thus serve as a rational target for the development of novel combination strategies. Citation Format: Marco A. De Velasco, Takashi Oki, Yurie Kura, Naomi Ando, Emiko Fukushima, Barry R. Davies, Dennis Huszar, Yutaka Yamamoto, Yuji Hatanaka, Nobutaka Shimizu, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Evaluation of Pim-1 kinase inhibition in a preclinical model of mouse prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1850. doi:10.1158/1538-7445.AM2015-1850
TCT-794 Expanding The Paradigm of Treatment in Infrapopliteal Arterial Occlusive Disease: Quality of Life Benefits of Transpedal Access Single Tibial Vessel Intervention
Authors: Apurva Patel, Roosha Parikh, Samuel Kolman, Jeffrey Ma, Justin Ratcliffe, Joseph Puma, Tak Kwan
Journal: Journal of the American College of Cardiology (2016)
Menopausal and sexual symptoms following radiotherapy in survivors of advanced cervical cancer.
Authors: Kameshwarachari Pushpalatha, Dayanand Sharma, Pramod Kumar Julka, Sunesh Kumar, G K Rath
Journal: Journal of Clinical Oncology (2012)

e15518 Background: With ever-increasing number of cancer survivors nearing 12 million, a majority of women will face vaginal health issues related to their disease and/or treatment. Hypothesis is that there is direct damage to ovarian follicles as a result of ionizing radiation leading to follicular atrophy and decrease in ovarian follicular reserve. Cancer treatment with radiotherapy induces menopause-causing estrogen-deprivation symptoms. Hence this study was conducted to investigate the frequency of radiation-induced menopausal and sexual symptoms in cervical cancer survivors Methods: A cross-sectional study was conducted between Feb-June 2011 on cohort of 55 advanced cervical cancer patients treated with pelvic radiation of 50.4 Gy in 28 fractions over 5.5 weeks and concurrent Cisplatin, followed by intracavitary boost of 15 Grays. Women aged 55 or older and/or postmenopausal at the time of the survey were excluded. By using a questionnaire, frequency of menopause was tried to elicit along with associated sexual symptoms like hot flushes, vaginal dryness, mood swings, dyspareunia, loss of libido, botheration. Results: The average age and parity were 38.8 years and 3.6 respectively. Amenorrhoea was found in all patients. 27 (49%) patients were asymptomatic. Among 28 (50.9%) symptomatic patients, we found hot flushes in 21 (38.2%), vaginal dryness in 38 (69%), mood swings in 12 (21.8%), dyspareunia in 27 (49%), loss of libido in 26 (47.2%), bothersome in 28 (50.9%). Conclusions: Menopausal symptoms were associated with other health-related issues known to compromise the quality of life. These results highlight the need to better acknowledge and define the utility of hormonal therapy in this population. Recommendations need to be provided to treating gynaecologists and Oncologists to identify, treat and promote vaginal health. Vaginal health issues can be reduced by dedicating a small duration of time to educate the cancer survivors on hormonal/non-hormonal vaginal health strategies.
Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events
Authors: Bhumika J Patel, Dayong Huang, Swapna Thota, Bartlomiej P Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Seishi Ogawa, Mikkael A. Sekeres, Hideki Makishima, Jaroslaw P. Maciejewski
Journal: Blood (2014)
Titanium-niobium pentoxide composites for biomedical applications
Authors: Yuncang Li, Khurram S. Munir, Jixing Lin, Cuie Wen
Journal: Bioactive Materials (2016)

The strength of titanium scaffolds with the introduction of high porosity decreases dramatically and may become inadequate for load bearing in biomedical applications. To simultaneously meet the requirements of biocompatibility, low elastic modulus and appropriate strength for orthopedic implant materials, it is highly desirable to develop new biocompatible titanium based materials with enhanced strength. In this study, we developed a niobium pentoxide (Nb
TCT-550 Influence of 12-month Late Incomplete Stent Apposition after Biolimus-eluting and Sirolimus-eluting Stent Implantation on 5-year Clinical Outcomes Following ST-segment Elevation Myocardial Infarction: Insigths from the SORT OUT V Trial Intravascular Ultrasound Substudy
Authors: Lisbeth Antonsen, Evald Christiansen, Michael Maeng, Jan Ravkilde, Knud Noerregaard Hansen, Lars Romer Krusell, Leif Thuesen, Mikkel Hougaard, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2016)
Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.
Authors: Patrizia Tosi, Elena Zamagni, Delia Cangini, Paola Tacchetti, Massimo Offidani, Sonia Ronconi, Giulia Perrone, Michela Ceccolini, Michele Baccarani, Sante Tura, Michele Cavo
Journal: Blood (2005)
TCT-774 Comparative Outcomes Study With Thoracic Endovascular Aortic Repair on Thoracic Aortic Aneurysm vs Thoracic Aortic Dissection: Single-Center Experience
Authors: Rafath Ullah, Khalil Odeh, Mirza Nubair Ahmad, M. Fuad Jan, Tanvir Bajwa
Journal: Journal of the American College of Cardiology (2016)
TCT-222 Clinical Outcomes of Dual Antiplatelet Therapy after Coronary Stenting in Patients with Chronic Kidney Disease: Patient-level Meta-analysis of 4 Randomized Clinical Trials
Authors: Doyeon Hwang, Joo Myung Lee, Tae-Min Rhee, Jonghanne Park, Kyung Woo (KW) Park, Myeong-Ki Hong, Yangsoo Jang, Marco Valgimigli, Antonio Colombo, Martine Gilard, Tullio Palmerini, Gregg Stone, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2016)
R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.
Authors: Ann LaCasce, Jonathan L. Vandergrift, Maria A. Rodriguez, Allison L. Crosby, Eva M. Lepisto, Myron S. Czuczman, Auayporn P. Nademanee, Douglas W. Blayney, Leo I. Gordon, Michael Millenson, Ann Vanderplas, Gregory A. Abel, Andrew D. Zelenetz, Jonathan W. Friedberg
Journal: Blood (2009)
Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies
Authors: K.R. Elliker, H.C. Williams
Journal: British Journal of Dermatology (2016)

When two U.K. dermatologists first reported that a pet dog spontaneously detected its owner's melanoma in 1989,1 a frenzy of media interest ensued. This was not surprising given the report had purported that the dog had saved the owner's life by catching the melanoma at a thin and curable stage. A number of additional cases of spontaneous cancer detection by dogs were then reported,2 and canine olfaction began to receive more focused scientific attention in the search for increasingly sensitive and specific diagnostic techniques for diseases where mass screening and/or early diagnosis could be improved.3 In 2004 the first experimental studies were published providing some ‘proof of principle’ that dogs could be specifically trained to detect cancer odours.4,5 Similar studies have since been conducted investigating lung, breast, prostate, colorectal and ovarian cancers.6,7,8,9 However, in this developing field of research, methods to test critically whether dogs can detect putative cancer odours are still being improved and optimized.6
TCT-845 Regional Differences in the Incidence and Outcomes of Hospitalization after Out-of-Hospital Cardiac Arrest in the United States
Authors: Nish Patel, Nileshkumar Patel, Shilpkumar Arora, Mauricio Cohen, Annapoorna Kini, Samin Sharma, Deepak Bhatt, Robert J. Myerburg
Journal: Journal of the American College of Cardiology (2016)
Generic oncology drugs: are they all safe?
Authors: Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage, Charles L Bennett
Journal: The Lancet Oncology (2016)
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study
Authors: K. Pandey, B. Pal, V.N.R. Das, K. Murti, C.S. Lal, N. Verma, S. Bimal, V. Ali, R.B. Verma, R.K. Topno, N.A. Siddiqi, P. Das
Journal: British Journal of Dermatology (2016)

PKDL is a dermal form of leishmaniasis caused by protozoal parasite Leishmania donovani. It is characterized by macular, popular and nodular lesions or a mixture of these1. It is mainly seen in Sudan and India, where it follows treatment of visceral leishmaniasis (VL) in 50% and 5-10% of cases respectively2. A phase III study on miltefosine-paromomycin combination for 10 days for treatment of Indian visceral leishmaniasis (n=157) revealed high cure rate (98.7%) with minimal toxicity, good compliance, lesser treatment duration and non-inferiority to standard amphotericin B3. We, therefore, aimed to assess the efficacy and safety of miltefosine plus paromomycin combination in thirty PKDL patients.

This article is protected by copyright. All rights reserved.
Prevalence of Immunosuppression Among US Adults, 2013
Authors: Rafael Harpaz, Rebecca M. Dahl, Kathleen L. Dooling
Journal: JAMA (2016)

immunosuppression increased with age, in parallel with the epidemiology of prevalent conditions that require immunosuppressive treatments, but it is unclear why it peaked at ages 50 to 59 years.The study has limitations.Self-reports of immunosuppression are prone to misclassification, but the modest range of results in the sensitivity analyses provides reassurance regarding the potential influence of erroneous responses.With a limited number of survey questions, causes or subsets of immunosuppression could not be reliably determined.It is unknown whether data from 2013 reflect the current prevalence of immunosuppression.In addition, the study excluded children and institutionalized adults.This study addresses an underappreciated phenomenon and serves as a call for additional data from other sources to complement and fill the gaps in the study.Tracking immunosuppression over time is particularly important given the hundreds of clinical trials now under way to assess the use of immunosuppressive treatments for prevention or mitigation of common chronic diseases in highly prevalent risk groups.